Skip to content

The effect and safety of hybrid electroconvulsive therapy (Hybrid-ECT) compared with routine electroconvulsive therapy in schizophrenia patients: a parallel-group, double-blinded, randomized, controlled, noninferiority pilot trial

The effect and safety of hybrid electroconvulsive therapy (Hybrid-ECT) compared with routine electroconvulsive therapy in schizophrenia patients: a parallel-group, double-blinded, randomized, controlled, noninferiority pilot trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033507
Enrollment
Unknown
Registered
2020-06-03
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Experimental group:HECT

Sponsors

Second People's Hospital of Huizhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Male or female patients aged 18 to 60 years; 2. Patients meet the following ICD-10 criteria and had an ECT indicationdepression (Schizophrenia or SFP); 3. The patients or legal guardians fully understand the treatment and agrees to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with poor efficacy of previous ect; 2. Patients who have done ect or rTMS in the past six months; 3. Patients with bipolar disorder and / or severe depressive episode without psychotic symptoms (ICD f31.4; f31.5); 4. For patients who use drugs incompatible with ECT (such as lithium, benzodiazepines, antiepileptics, etc.), these drugs should be stopped at least before ECT treatment; 5. Patients unable to follow the protocol; 6. Epilepsy history of patients with serious or unstable major diseases (Parkinson's disease, multiple sclerosis, stroke, substance dependence, etc.); 7. Lactation, pregnant women and patients who are pregnant or intend to be pregnant during the clinical study.

Design outcomes

Primary

MeasureTime frame
PANSS;

Countries

China

Contacts

Public ContactZhaoyun Jiang

Second People's Hospital of Huizhou

1286471669@qq.com+86 13322620923

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026